×

Stabilized formulations of CNS compounds

  • US 10,149,853 B2
  • Filed: 04/25/2014
  • Issued: 12/11/2018
  • Est. Priority Date: 03/31/2010
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical formulation comprising molindone as a single active pharmaceutical ingredient and having:

  • (a) a modified-release formulation comprising;

    (i) molindone,(ii) at least one release controlling polymer, wherein the release controlling polymer (1) consists of one or more pH-dependent polymers selected from the group consisting of poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate), methacrylic acid-ethyl acrylate copolymer, methacrylic acid-ethyl acrylate copolymer dispersion, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and zein and (2) does not comprise non-pH-dependent polymers, and(iii) at least one stabilizer selected from the group consisting of acidifying agents and hydrophobizing agents; and

    , optionally,(b) an additional formulation comprising molindone in an immediate release, extended release, or delayed release formulation.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×